parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in cone photoreceptor cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 67	0.91
pathways Reactome	8 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 13465

MCF2L in dopamine neurons, braak-0.61 (p 0.084) → -0.49 (p 0.186)receipt 13473
MCF2L in microglia, braak-0.32 (p 0.407) → -0.11 (p 0.787)receipt 13472

receipt 13473: MCF2L in dopamine neurons, braak

power: full sample -0.53 (p 0.023, n 18), 95% CI -0.80 to -0.09. the interval excludes zero: something may be there, smaller than a half can see.
confounder: adjusted for sex: -0.51 (p 0.032, n 18). holds up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.65 (p 0.0033, n 18). not the mix.
skeptic: leave-one-out range -0.64 to -0.47, sign flips 0; without severely affected donors -0.53 (p 0.023, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MCF2L in dopamine neurons.

case closed: nothing better to follow up.

receipt 13472: MCF2L in microglia, braak

power: full sample -0.15 (p 0.561, n 18), 95% CI -0.57 to +0.34. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.07 (p 0.774, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.02 (p 0.935, n 18). could be the mix.
skeptic: leave-one-out range -0.31 to -0.03, sign flips 0; without severely affected donors -0.15 (p 0.561, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MCF2L in microglia.

case closed: nothing better to follow up.

loading the receipts